Bank of America’s TherapeuticsMD TXMD Stock Holding History

Bank of America’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,000	Closed	-$2.6M	–	7507
2019 Q2	$2.6M	Buy	+20,000	New	+$3.59M	﹤0.01%	3824

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's TXMD Position: Q1 2026 in Review

Bank of America sold out of TherapeuticsMD (TXMD) in Q1 2026, closing a stake of 108 shares — an estimated $176 sold.

Bank of America first reported a position in TXMD in Q2 2013 and held it in 51 quarters. The position peaked at $5.09M in Q2 2019. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

Bank of America reported no remaining TherapeuticsMD position as of Q1 2026 after selling out during the quarter.
Bank of America sold 108 TherapeuticsMD shares in Q1 2026, an estimated $176.
Bank of America first reported a position in TherapeuticsMD in Q2 2013 and held it in 51 quarters.
Bank of America's TherapeuticsMD position peaked at $5.09M in Q2 2019.
49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.